According to research compiled by Reports and Data, in 2018 the global biologics market was valued at over $250 million, but is projected to reach an estimated $625 million by the end of 2026 with an 11.9% compound annual growth rate (CAGR). Biologics are medications made up of proteins, sugars, or DNA, and oftentimes are a complex combination of these materials and by-products. Biologics can also be composed of living cells and tissues and come in a wide variety of products such as allergy medicines, vaccines, oncology treatments, therapeutics, amongst…
New data suggests Cytokine Release Syndrome in patients with severe cases of COVID-19 may cause death. See how BioAgilytix can apply our validated MSD cytokine/chemokine panels to support cytokine monitoring in COVID-19 vaccine & therapeutic programs.
Many great questions were asked by our audience during Dr. Afshin Safavi’s recent webinar on exploratory biomarker testing. We've compiled his answers those he didn’t have time to address during the live session.
Biomarkers are endogenous molecules with much individual variability, and there is still not yet one clear and concise guidance for biomarker validation – so there are still questions around what it takes to sufficiently validate the performance characteristics of a biomarker assay to ensure it can properly establish the value of the target biomarker as a qualified DDT.
A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish consensus on the expectations for the validation of assays used in the regulatory qualification of fluid biomarkers.
The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive 2017/746) and research use only (RUO) kits are used to support the biomarker analysis needed in clinical trials because both types of assays have different strengths and limitations. To select the appropriate kit requires an understanding of these pros and cons in the context of the intended study the assay must support.
There is no doubt that our genetic makeup is different. Yet surprisingly, biology is often an overlooked consideration in ensuring biomarker assays are set up and validated to support the intended study.
When assessing biomarkers for multifactorial diseases, we ideally want to assess multiple analytes in the same experiment. That is where the value of multiplex biomarker analysis comes in – but this method also inherently creates potential challenges with cross-reactivity. We discuss how the ProteinSimple Ella platform enables multiplexing with excellent assay reproducibility, and how it can benefit studies with low sample volumes.
We find it critical to stay on top of the latest industry developments to inform our own work and help our customers best address emerging bioanalytical challenges and opportunities; we've compiled some of our favorite recent industry articles of interest to share with you.
Biomarkers have the potential to inform the drug development process for both large and small molecule drugs. Learn more about our ability to carry out a wide variety of biomarker testing for both types of drugs.